Skip to main content

Table 2 Univariate and multivariate analyses

From: Decreased hormonal sensitivity after childbirth rather than the tumor size influences the prognosis of very young breast cancer patients

Factors Univariate analysis Cox’s proportional hasard model
  Logrank test   95% CI  
Cases Recurrence/died 10 year RFS (%) P value HR Lower limit Upper limit P value
Calendar year of surgery
 1986–1995 80 35 65.7 0.5963     
 1996–2002 80 32 61.0      
Family history of breast cancer
 None 138 58 64.9 0.9870     
 Positive 22 9 56.9      
Years from the last delivery (YFLC)
 Nulliparous 84 42 59.4 0.1208 1    
 Recent (<8) 20 9 58.7   0.731 0.317 1.686 0.4618
 Past (≥8) 56 16 72.0   0.422 0.186 0.956 0.0387
 Past 56 16 72.0 0.0399     
 Nulliparous/Recent 104 51 59.3      
Tumor size, cm (Pathological)
 ≤5 113 43 67.0 <0.0001 1    
 >5 17 13 23.5   1.426 0.520 3.912 0.4911
The number of metastatic lymph nodes
 None 78 25 74.9 <0.0001 1    
 1–3 47 17 72.1   1.812 0.805 4.079 0.1512
 4–9 19 12 36.8   3.388 1.363 8.425 0.0086
 10– 15 13 13.3   6.714 2.033 22.177 0.0018
Histological typea
 Papillotubular carcinoma 45 10 83.7 0.0149 1    
 Sollid-tubular carcinoma 44 19 58.2   3.348 1.352 8.292 0.0090
 Scirrhous carcinoma 57 30 55.4   2.294 1.013 5.197 0.0465
 Special types 14 8 50.0   2.816 0.887 8.944 0.0791
Extent of tumor invasion (histological)
 Localized within gland or fat 149 60 65.7 0.0072 1    
 Invading the skin and/or muscle 11 7 36.4   2.455 0.888 6.787 0.0834
Lymphovascular invasion
 Absent 98 33 71.7 0.0015 1    
 Present 62 34 50.6   1.883 0.966 3.696 0.0629
Estrogen receptor(EIA), fmol/mg
 <5 (negative) 61 28 62.9 0.3093     
 5–21 (weakly positive) 32 12 61.1      
 22– (strongly positive) 28 13 53.1      
 Not performed 39 14 76.0      
Progesterone receptor(EIA), fmol/mg
 <10 (negative) 43 21 56.7 0.1221     
 10–95 (Weakly positive) 35 17 54.0      
 96– (strongly positive) 40 14 68.8      
 Not performed 42 15 75.0      
 Negative/weakly positive 78 38 55.2 0.0189 1    
 Strongly positive/Not performed 82 29 71.9   0.679 0.361 1.274 0.2278
Type of breast surgery
 Breast conserving surgery (BCS) 43 15 71.3 0.4737     
 Mastectomy 117 52 61.3      
Chemotherapy
 Others, none 68 23 72.9   1    
 Anthracycline/Taxane/CMF 92 44 56.8 0.0136 0.714 0.342 1.489 0.3689
Hormone therapy
 Ovarian Function Suppression ± Others 18 5 67.3 0.6537     
 Selective estrogen receptor modulators 36 15 59.5      
 Others, none 106 47 64.2      
Radiation therapy (RT)
 Not performed 131 54 65.6 0.2767     
 Performed 29 13 53.7      
Age at surgery
 Case (younger than 30) 80 37 61.7 0.3865 0.557 0.251 1.239 0.1515
 Control (elder counterpart) 80 30 65.6   1    
  1. aCategory “Unilateral double cancer” was re-classified to the histological type of the larger invasive tumor.